CYV
CERYVYNTHERAPEUTICS ORDINARYCeryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
CYV
CYV
CERYVYNTHERAPEUTICS ORDINARY
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).
Fundamentals
Historical Data38 days
| Date | Short % | Gross Short |
|---|---|---|
| 28 Aug | — | — |
| 27 Aug | — | — |
| 26 Aug | — | — |
| 25 Aug | 0.31% | — |
| 24 Aug | 0.31% | — |
| 21 Aug | 0.31% | — |
| 20 Aug | 0.31% | — |
| 19 Aug | 0.31% | — |
| 18 Aug | 0.31% | — |
| 17 Aug | 0.31% | — |
| 14 Aug | 0.31% | — |
| 13 Aug | 0.31% | — |
Ceryvyntherapeutics (CYV) Short Interest Summary
Ceryvyntherapeutics (CYV) currently has 0.31% of its shares sold short (4.2 million shares, worth approximately $42K), based on ASIC short position data reported on 25 August 2026 (T+4 reporting lag). That makes CYV the #365 most shorted stock on the ASX most shorted list. Short interest in CYV is up 0.00% over the past week and up 0.00% over the past month. CYV is part of the Health Care sector on the ASX.
Recent CYV Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 25 Aug 2026 | 0.31% | 4.2M | $0.01 |
| 24 Aug 2026 | 0.31% | 4.2M | $0.01 |
| 21 Aug 2026 | 0.31% | 4.2M | $0.01 |
| 20 Aug 2026 | 0.31% | 4.2M | $0.01 |
| 19 Aug 2026 | 0.31% | 4.2M | $0.01 |
| 18 Aug 2026 | 0.31% | 4.2M | $0.01 |
| 17 Aug 2026 | 0.31% | 4.2M | $0.01 |
| 14 Aug 2026 | 0.31% | 4.2M | $0.01 |
| 13 Aug 2026 | 0.31% | 4.2M | $0.01 |
| 12 Aug 2026 | 0.31% | 4.2M | $0.01 |
CYV Short Selling — Frequently Asked Questions
What is Ceryvyntherapeutics (CYV)'s current short interest?
Ceryvyntherapeutics (CYV) currently has a short interest of 0.31% of total shares outstanding. This means 0.31% of CYV's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is CYV heavily shorted on the ASX?
CYV has a relatively low short interest of 0.31%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for CYV investors?
Short interest in CYV shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.31%, CYV's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this CYV short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for CYV.